Table 1: Metabolism and Transport Effects (10-13) Arimidex Aromasin
Femara Tamoxifen CYP1A2 weakly inhibits CYP2A6 minor substrate minor weakly substrate inhibits weakly inhibits CYP3A4 weakly major substrate minor major substrate inhibits weakly induces substrate weakly inhibits CYP2B6 minor substrate weakly inhibits CYP2C8 weakly weakly inhibits inhibits CYP2C9 weakly major substrate inhibits weakly inhibits CYP2C19 weakly inhibits CYP2D6 major substrate CYP2E1 minor substrate + minor substrate ++ major substrate [down arrow] weakly inhibits [down arrow] [down arrow] strongly induces [up arrow] weakly inhibits
ISLAMABAD -- In what may be seen as a positive development, it has emerged that the anti-estrogen drug Aromasin
reduces the risk of breast cancer recurrence by about one-third in postmenopausal women previously treated with tamoxifen.
Aromatase inhibitors (Arimidex, Aromasin
, or Femara) have fewer side effects and more benefits than tamoxifen.
Exemestane is marketed as Aromasin
by its maker Pfizer, which funded the study.
s (New York) breast-cancer drug Aromasin
and similar treatments from AstraZeneca Plc (London GBR) and Novartis AG (Basel CHE) make women 26% more likely to develop heart disease than an older therapy, a study found.
Exemestane, marketed as Aromasin
, works by shutting off production of the female hormone oestrogen, which fuels the majority of breast cancer tumours.
AIs, such as the drug aromasin
, suppress production of the female sex hormone oestrogen, which fuels the growth of most breast tumours.
The Government's drugs watchdog has approved the use of Arimidex, Femara and Aromasin
alongside "gold standard" drug Tamoxifen.
They are Arimidex (anastro-zole), Femara (letrozole) and Aromasin
(exemestane) and will be available on the NHS alongside the "gold standard" drug tamoxifen.
They are Arimidex, Femara and Aromasin
and will be available on the NHS alongside the "gold standard" drug tamoxifen.
The case for the new aromatase inhibitors - like Femara, Aromasin
and Arimidex - stop the natural production of oestrogen - the hormone that is responsible for the growth and recurrence of many breast cancers.
The guidance, which relates to Femara (letrozole), Aromasin
(exemestane) and Arimidex (anastrozole), is preliminary and subject to consultation.